Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Two Salvage Chemotherapy Regimens Evaluated in AML

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Muluneh, et al

Two different kinds of salvage chemotherapy regimens produced similar outcomes in a study involving 41 individuals with relapsed/refractory acute myeloid leukemia (rrAML). However, 1 treatment was substantially less expensive. Participants with rrAML were treated with either clofarabine- (GCLAC; n=22) or cladribine- (CLAG; n=19) based therapy. Investigators looked at complete response rate, percentage of patients who underwent allogenic stem cell transplant (allo-SCT), relapse free survival, and overall survival. The small trial did not produce statistically significant differences in:

  • Complete remission with or without hematologic recovery: 64% for GCLAC, 47% for CLAG.
  • Percentage of patient who underwent allo-SCT: 45% and 25%, respectively.
  • Relapse-free survival: 1.59 vs 1.03 years, respectively.
  • Overall survival: 1.03 vs 0.70 years, respectively.

The average wholesale price was nearly $61,000/patient/cycle for GCLAC, vs nearly $5,000 for CLAG.


Muluneh B, Buhlinger K, Deal A, et al. A Comparison of clofarabine-based (GCLAC) and cladribine-based (CLAG) salvage chemotherapy for relapsed/refractory AML. [Published online ahead of print September 22, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.016.

This Week's Must Reads

HIT Incidence During Obstetric Hospital Admissions, Am J Perinatol.; ePub 2018 Feb 8; Sagaram, et al

Endoscopy for GI Bleeds in Severe Thrombocytopenia, Gastrointest Endosc; ePub 2018 Feb 1; Ramos, et al

Does This Predict Acute Pain in Children with SCD? , Am J Hematol; ePub 2018 Jan 25; Willen, et al

Ibuprofen Use in Alcohol-Related Thrombocytopenia , Hosp Pharm; 2018 Feb; Muhammad, Tomko, et al

Romiplostim-Treated Patients: No Increased AML Risk, Lancet Haematol; ePub 2018 Jan 25; Kantarjian, et al

Must Reads in AML

Outcomes in Older Transplant Patients with AML/MDS , Biol Blood Marrow Transplant; ePub 2017 Dec 27; Tsai, et al

Venetoclax Regimens Assessed in Patients with AML, Am J Hematol; ePub 2017 Dec 23; DiNardo, et al

Two Salvage Chemotherapy Regimens Evaluated in AML, Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Muluneh, et al

Cochrane on Optimizing Chemo, Radiotherapy for HL, Cochrane; 2017 Sep 4; Franklin, Eichenauer, et al

FDA Approves Mylotarg for Certain Form of AML, Wyeth news release; 2017 Sep 1